Sugi Predict

Sugi Predict / Compounds / SCHEMBL391518

SCHEMBL391518

SCHEMBL391518

CNC1CN(C(=O)OC(C)(C)C)CC1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.46
▸ USP30 Q70CQ3 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ EPHX1 P07099 1/20 0.40
▸ NAMPT P43490 1/20 0.39
▸ CHRM2 P08172 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ EPHX2 P34913 1/20 0.38
▸ PDE4B Q07343 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ PTPN2 P17706 1/20 0.37
▸ PTPN1 P18031 1/20 0.37
▸ PTPN6 P29350 1/20 0.37
▸ DDB1 Q16531 1/20 0.36
▸ CRBN Q96SW2 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL762294 1.00 NR1H2 (0.46) NR1H2USP30USP2SMN1; SMN2EPHX1
SCHEMBL3567347 1.00 NR1H2 (0.46) NR1H2USP30USP2SMN1; SMN2EPHX1
SCHEMBL19881453 1.00 NR1H2 (0.46) NR1H2USP30USP2SMN1; SMN2EPHX1
SCHEMBL13282934 1.00 NR1H2 (0.46) NR1H2USP30USP2SMN1; SMN2EPHX1
SCHEMBL14303516 1.00 NR1H2 (0.46) NR1H2USP30USP2SMN1; SMN2EPHX1
SCHEMBL12458213 0.89 NR1H2 (0.45) NR1H2USP30USP2SMN1; SMN2EPHX1
SCHEMBL31084556 0.86 EPHX1 (0.47) NR1H2USP2SMN1; SMN2EPHX1HPGD
SCHEMBL18502917 0.86 EPHX1 (0.47) NR1H2USP2SMN1; SMN2EPHX1HPGD
SCHEMBL20121454 0.86 EPHX1 (0.47) NR1H2USP2SMN1; SMN2EPHX1HPGD
SCHEMBL24098660 0.85 NR1H2 (0.45) NR1H2USP30USP2SMN1; SMN2EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637426-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2026-05-26 — — US disclosed
CN-112707893-B 1-cyanopyrrolidine compounds as USP30 inhibitors 特殊治疗有限公司 2023-10-31 — — CN disclosed
US-20220251041-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LTD (GB) 2022-08-11 — — US disclosed
US-11390584-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2022-07-19 — — US disclosed
EP-3943490-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2022-01-26 — — EP disclosed
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-20 — — US disclosed
EP-3277677-B9 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LTD (GB) 2021-07-14 — — EP disclosed
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-06 — — US disclosed
EP-3842427-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2021-06-30 — — EP disclosed
EP-3277677-B1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LTD (GB) 2021-02-24 — — EP disclosed
US-8637491-B2 Thieno-pyridine derivatives as MEK inhibitors UCB PHARMA S.A. (BE) 2014-01-28 — — US disclosed
US-8101764-B2 MCH receptor antagonists ELI LILLY AND COMPANY (US) 2012-01-24 — — US disclosed
US-20110172191-A1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS UCB PHARMA S.A. (BE) 2011-07-14 — — US disclosed
EP-2315768-A1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS UCB Pharma, S.A. (BE) 2011-05-04 — — EP disclosed
US-20100016350-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2010-01-21 — — US disclosed
WO-2009153554-A1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS UCB PHARMA S.A. (BE) 2009-12-23 — — WO disclosed
EP-2029610-A2 NOVEL MCH RECEPTOR ANTAGONISTS Eli Lilly & Company (US) 2009-03-04 — — EP disclosed
WO-2007146759-A2 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2007-12-21 — — WO disclosed
WO-2006070284-A1 PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS PFIZER PRODUCTS INC. (US) 2006-07-06 — — WO disclosed
EP-0485952-A2 Process for production of 3-amino-4-methylenepyrrolidine derivatives SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) 1992-05-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 NR1H2 3516/4885USP30 1/4885USP2 10/4885
US-20110172191-A1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS MAP2K2, MAP2K1, MAP2K3 NR1H2 3188/4885USP30 2621/4885USP2 2977/4885
US-20220251041-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 NR1H2 4002/4885USP30 1/4885USP2 9/4885
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 NR1H2 4002/4885USP30 1/4885USP2 9/4885
US-20100016350-A1 NOVEL MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R NR1H2 252/4885USP30 2497/4885USP2 3272/4885
US-12637426-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP1, USP10 NR1H2 2913/4885USP30 1/4885USP2 8/4885
US-11390584-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 NR1H2 4038/4885USP30 1/4885USP2 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.